

## Hybrigenics: continuous trading from June 10

**Paris, June 9, 2009** – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris with a focus on the research and development of new cancer treatments and specialized in protein interactions, today announces its continuous trading from June 10, 2009 and the result of the exercise of warrants expired on April 30, 2009.

### □ **Continuous trading from June 10, 2009**

In view of the recent increase in daily volumes of share exchanges, Hybrigenics has decided to opt for continuous trading. All-day electronic trading of Hybrigenics shares will become effective on June 10, 2009.

*"The publication of our excellent business figures for the first quarter of 2009, combined with the serious interest raised by the preliminary Phase II results of inecalcitol in prostate cancer patients unveiled at the annual congress of the American Society of Clinical Oncology, recently triggered a sharp increase in Hybrigenics' volumes of shares exchanged at its daily fixing. We now expect continuous trading to better serve shareholders' liquidity needs",* commented Rémi Delansorne, Hybrigenics' CEO.

### □ **7,413 warrants exercised**

Warrants had been attached to shares issued at the time of IPO in December 2007 and new terms were implemented in November 2008 with an expiry date on April 30, 2009, resulting in 7,413 warrants being exercised with the issuance of 22,239 new shares.

### **About Hybrigenics** (ISIN: FR0004153930, Mnemo: ALHYG)

Hybrigenics ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere<sup>®</sup>, which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

Hybrigenics is also the market leader in Yeast-Two Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

\*\*\*

**Hybrigenics**  
**Remi Delansorne**  
CEO  
Tel. : +33 (0)1 58 10 38 00  
[investors@hybrigenics.com](mailto:investors@hybrigenics.com)

**NewCap.**  
Financial Communication  
Axelle Vuillermet / Pierre Laurent  
Tel. : +33 (0)1 44 71 94 94  
[hybrigenics@newcap.fr](mailto:hybrigenics@newcap.fr)